Delphinus Medical Technologies, maker of the SoftVue whole breast ultrasound system, has named Mark J. Forchette as its president and chief executive officer. An established executive, Forchette has experience with driving innovative technologies to grow market share.
“The board of directors is delighted with Mark’s appointment as president and CEO,” said Paul McCreadie, managing director of Arboretum Ventures and chairman of the board of Delphinus. “He brings outstanding energy and leadership to Delphinus, a remarkable record of success, and a deep passion for introducing new technologies that improve the lives of many. Mark’s expertise and leadership bring a fresh trajectory to the organization that will benefit Delphinus greatly as we advance our regulatory and commercial objectives.”
Forchette previously served as president and CEO of OptiMedica Corporation, an ophthalmic medical device start-up company that was acquired by Abbott Laboratories in 2013. He started his medtech career at Greishaber and Company, Inc, where he led the company as vice president of US sales and marketing until its acquisition by Alcon. While at Alcon, he became vice president of vitreoretinal sales and global marketing, overseeing the retina portfolio.
“Delphinus’ SoftVue technology is stunning, and the opportunity to lead the team into the future is truly compelling,” said Forchette. “I have experienced how impactful transformative technologies can be in establishing a paradigm shift in both practice technique and clinical results. The imaging innovation of SoftVue is poised as that breakthrough advancement to improve breast cancer detection and diagnosis, particularly for women with dense breast tissue, where there is a true need for new technologies in breast cancer screening.”
For more information, visit Delphinus Medical Technologies.